Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series

The development of complement inhibitors has greatly improved the outcome of patients with atypical hemolytic uremic syndrome (aHUS), making kidney transplantation a more feasible option. Although prophylactic eculizumab therapy may prevent recurrent disease after transplantation, its necessity for all transplant recipients is debated.

http://ift.tt/2uKeZGD